Overview

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

Status:
Not yet recruiting

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Oana Danciu

Collaborator:

Novartis Pharmaceuticals

Treatments:

Anastrozole
Exemestane
Fulvestrant
Letrozole